Cover Image
市場調查報告書

NPS+:乾癬 (歐盟5國)

NPS+ Psoriasis 2017 (EU)

出版商 FirstWord 商品編碼 497071
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
NPS+:乾癬 (歐盟5國) NPS+ Psoriasis 2017 (EU)
出版日期: 2017年04月01日 內容資訊: 英文
簡介

本報告依據歐盟5國 (法國、義大利、德國、西班牙、英國)的150名皮膚科醫生的調查結果,提供乾癬治療藥的領導品牌8項產品的醫生的使用趨勢和各種見解的比較、分析,支援客戶的忠誠度的NPS (淨推薦值) 指標的改善。

主要8項品牌藥

  • Benepali (Etanercept:Biogen)
  • Cosentyx (secukinumab:Novartis)
  • Enbrel (Etanercept:Pfizer)
  • Humira (Adalimumab:AbbVie)
  • Inflectra (Infliximab:Pfizer)
  • Otezla (apremilast:Celgene)
  • Remicade (Infliximab:Merck Sharp & Dohme)
  • Remsima (Infliximab:Napp/Mundipharma)
  • Stelara (Ustekinumab:Janssen Cilag)
  • Taltz (ixekizumab:Eli Lilly)

調查內容範例:影響品牌忠誠的主要課題

  • 醫生對乾癬治療藥的滿意度
  • 醫生對特定品牌藥的忠誠度等級
  • 特定品牌推薦者推薦的其他品牌數
  • 特定品牌推薦者、批判者推薦的其他品牌
  • 在推薦者及批判者間的特定品牌的市場佔有率
  • 如果批判者成為了推薦者可取得的市場佔有率
  • 推薦者、中立者、批判者為特定品牌相關訊息
  • 品牌DNA:特定品牌藥相關的醫生的話
目錄

Biosimilars take the biggest hit as doctors voice dissatisfaction with psoriasis treatments

Dermatologists say they're satisfied with available psoriasis treatments. So why did only 3 of the brands we asked them about get positive satisfaction scores? The candid comments in this report shed some light on doctors' major concerns-especially with biosimilar brands, which fared worse than other treatments, but stand to make big market share gains if they can win over Detractors..

Find out how doctors rated your brand, get insight into why, and learn what you can do to boost your score in FirstView's NPS+ Psoriasis 2017 (EU5) .

Building on the respected net promoter score (NPS), the report compares ten major psoriasis drugs with easy-to-use KPIs that highlight ways you can improve brand health. You'll also see how loyal doctors are to your brand, learn which promotional messages resonate best, and find out what doctors think in a unique "Brand DNA" section.

Top Takeaways

  • Most brands fare poorly: Only three of the ten surveyed brands earned a positive net promoter score (NPS).
  • Biosimilars get the brunt of it: Not only did they score lowest, biosimilar brands have by far the most Detractors. The report's Brand DNA section may hold clues as to why.
  • Most doctors say they are satisfied: Only about 20% of surveyed doctors claim they aren't satisfied with available brands.
  • Half of the surveyed brands are poised for big gains: 5 of them are poised to increase their market share by 500% to 1000% percent or more if they can win over Detractors.
  • Promotional messages aren't always landing: For several brands, few promotional messages resonate with many of the surveyed doctors.
  • Don't expect brand loyalty: Just over 10% of surveyed doctors promote one brand exclusively. Loyalty scores are low across the board, and especially for the two lowest-ranked brands

Insight into 8 Major Psoriasis Brands

  • Benepali (etanercept; Biogen)
  • Cosentyx (secukinumab; Novartis)
  • Enbrel (etanercept; Pfizer)
  • Humira (adalimumab; AbbVie)
  • Inflectra (infliximab; Pfizer)
  • Otezla (apremilast; Celgene)
  • Remicade (infliximab; Merck Sharp & Dohme)
  • Remsima (infliximab; Napp/Mundipharma)
  • Stelara (ustekinumab; Janssen Cilag)
  • Taltz (ixekizumab; Eli Lilly)

A Report Based on Expert Knowledge

We surveyed 150 dermatologists from the EU5 countries (France, Italy, Germany, Spain, UK) , chosen from the largest community of validated physicians in the world. The same community that pharma market researchers trust for reliable, fast intelligence.

We conducted the survey between March 2nd and 8th, 2017.

Explore Important Brand Loyalty Issues

NPS+ Psoriasis 2017 (EU5) explores key issues affecting brand loyalty for drug manufacturers. You'll learn:

  • How satisfied doctors are with available treatments.
  • How loyal doctors are to your brand.
  • How many other brands your Promoters recommend.
  • Which other brands your Promoters and Detractors recommend.
  • How much market share your brand has among Promoters and Detractors.
  • How much market share you stand to gain by converting Detractors into Promoters.
  • Which messages Promoters, Passives and Detractors associate with your brand.
  • Your brand DNA: what doctors really think of your brand-in their own words.

What is Net Promoter® Score?

NPS is a customer loyalty metric developed by (and a registered trademark of) Fred Reichheld, Bain & Company, and Satmetrix. It was introduced by Reichheld in his 2003 Harvard Business Review article One Number You Need to Grow.

How does NPS work?

NPS measures overall brand satisfaction and loyalty by asking one simple question:

"How likely are you to recommend this brand to a colleague?"

Responses - given on a scale of 0 (not at all likely) to 10 (extremely likely)-are used to classify respondents into 3 categories:

  • Detractors are those who answer 0 - 6.
  • Passives are those who answer 7 - 8.
  • Promoters are those who answer 9 - 10.

How is NPS calculated?

The percentage of detractors - the percentage of promoters = NPS.

For example, 25% Promoters, 55% Passives and 20% Detractors give you an NPS of +5.

NPS can range from -100 (everybody is a Detractor) to +100 (everybody is a Promoter). The higher the score the healthier the brand.

What is FirstView NPS+?

NPS+ turns your Net Promoter Score into actionable information by answering key questions about brand loyalty.

Each NPS+ report examines doctors' relationships with the brands used to treat a major disease area-measuring brand loyalty and showing you how it affects your market share. NPS+ also examines "brand DNA", revealing in doctors' own words what brands mean to them.

Instead of one simple metric, NPS+ gives you a detailed picture of brand health that highlights areas for improvement, and helps you see exactly what steps you need to take next.

Back to Top